These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
95 related items for PubMed ID: 6215419
1. Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease. Harris ST, Neer RM, Segre GV, Petkau AJ, Tully GL, Daly M, Potts JT. J Clin Endocrinol Metab; 1982 Dec; 55(6):1100-7. PubMed ID: 6215419 [Abstract] [Full Text] [Related]
2. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. Delmas PD, Chapuy MC, Vignon E, Charhon S, Briancon D, Alexandre C, Edouard C, Meunier PJ. J Clin Endocrinol Metab; 1982 Apr; 54(4):837-44. PubMed ID: 6460781 [Abstract] [Full Text] [Related]
5. Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone. Meunier PJ, Chapuy MC, Alexandre C, Bressot C, Vignon E, Trechsel U, Mathieu L, Edouard C. Adv Exp Med Biol; 1980 Apr; 128():299-309. PubMed ID: 6448538 [No Abstract] [Full Text] [Related]
6. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Douglas DL, Duckworth T, Russell RG, Kanis JA, Preston CJ, Preston FE, Prenton MA, Woodhead JS. Lancet; 1980 May 17; 1(8177):1043-7. PubMed ID: 6103389 [Abstract] [Full Text] [Related]
7. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate. Chapuy MC, Charhon SA, Meunier PJ. Metab Bone Dis Relat Res; 1983 May 17; 4(6):325-8. PubMed ID: 6229683 [Abstract] [Full Text] [Related]
8. Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP). Adami S, Guarrera G, Salvagno G, Spiazzi G, Marini G, Rosini S, Lo Cascio V. Metab Bone Dis Relat Res; 1984 May 17; 5(6):265-7. PubMed ID: 6238218 [Abstract] [Full Text] [Related]
10. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Adami S, Zamberlan N, Mian M, Dorizzi R, Rossini M, Braga B, Gatti D, Bertoldo F, Locascio V. Bone Miner; 1994 May 17; 25(2):75-82. PubMed ID: 8086853 [Abstract] [Full Text] [Related]
12. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone. Devlin RD, Retallack RW, Fenton AJ, Grill V, Gutteridge DH, Kent GN, Prince RL, Worth GK. J Bone Miner Res; 1994 Jan 17; 9(1):81-5. PubMed ID: 8154313 [Abstract] [Full Text] [Related]
13. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment. Polyzos SA, Anastasilakis AD, Makras P, Terpos E. Exp Clin Endocrinol Diabetes; 2011 Oct 17; 119(9):519-24. PubMed ID: 21811962 [Abstract] [Full Text] [Related]